This $481,250 Project Grant was awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to Vanderbilt University Medical Center (VUMC) on September 1, 2024. The award supports the development of an innovative, non-invasive MRI imaging technique to assess membrane lipid properties in Alzheimer's disease (AD). The key objectives are to: 1) verify the relationship between the MRI nuclear Overhauser enhancement (NOE) signal and lipid properties using reconstituted phospholipid...
This $4.49 million project grant from the National Institutes of Health's National Institute on Aging will fund research at The Washington University to investigate the relationship between amyloid plaque deposition, cellular metabolic dysfunction, and functional brain organization in Alzheimer's disease (AD) mice models. Over three years, the researchers will use multi-photon fluorescence lifetime imaging microscopy, multi-parametric photoacoustic microscopy, and wide-field optical imaging to...
This $342,934.65 project grant from the Department of Health and Human Services National Institutes of Health National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research into acyl chain remodeling and regional lipid dysregulation in Alzheimer's disease. The Trustees of Columbia University in the City of New York, doing business as Health Sciences Division, will analyze lipid composition in brain regions susceptible to Alzheimer's disease, such as the...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $795,542 to the University of California, Davis to study lipid mediator pathways involved in neuronal survival and repair in Alzheimer's disease (AD). The key goals are to understand whether neuronal loss in AD is caused by deficits in the supply of free "pro-repair" lipid mediators from brain lipid pools, and to test whether replenishing these lipid mediator pools can provide...
This Project Grant award of $328,000 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the Alzheimer's Disease Organelle Proteome Task (ADOPT) pilot phase. The interdisciplinary research team, led by Drs. Biao Wang and Danielle Swaney at the University of California, San Francisco, will use a genetic organelle tagging approach to rapidly purify lysosomes from neurons in wild-type and Alzheimer's disease mouse models. A suite of mass spectrometry experiments will then...
The National Institute on Aging (NIA) awarded a $400,707 Project Grant (CFDA 93.866 - Aging Research) to the University of Florida to map brain lipid architecture in aging, Lewy body dementia (LBD), and T-cell therapy. The 2-year grant, running from September 1, 2024 to August 31, 2026, will utilize novel imaging mass spectrometry to generate a spatial atlas of the lipidome and identify lipid markers of disease progression in LBD. The research aims to assess lipid alterations resulting from an...
The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $2,273,637 Project Grant to The Johns Hopkins University to conduct a comprehensive study of plasma and brain lipidomics (lipid profiling) and their associations with Alzheimer's disease (AD), dementia, and cognitive decline. The study will leverage novel Lipidyzer technology to quantify over 1,500 lipid species in plasma samples from 3,868 participants in the Cardiovascular Health...
This $4.2 million project grant from the National Institutes of Health's National Institute on Aging will fund research into the mechanisms by which the ABCA7 gene influences Alzheimer's disease. The Trustees of the University of Pennsylvania will investigate the specific lipid species affected by deletion of ABCA7 in three types of induced pluripotent stem cell-derived brain cells. Researchers will also identify ABCA7 protein domains that differentiate its functions from ABCA1 and...
This $4.4 million project grant from the National Institute on Aging, part of the Department of Health and Human Services, will fund research into developing a non-invasive stem cell-derived extracellular vesicle therapy for Alzheimer's disease. Over a three-year period from August 2022 to July 2025, researchers at Texas A&M University Health Science Center will test the hypothesis that intranasal administration of extracellular vesicles generated from human-induced pluripotent stem...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), aims to develop novel lipid nanoparticle (LNP) formulations for delivering nucleic acid-based therapeutics to the brain for treating Alzheimer's disease (AD). The $835,417 award will support research to synthesize BBB-crossing lipids, formulate LNP-RNA constructs, elucidate their trafficking across the blood-brain barrier, engineer siRNA and mRNA sequences to modulate APOE...
LIPID IMAGING EXPANSION MICROSCOPY TO STUDY ALZHEIMER'S DISEASE - ALZHEIMER'S DISEASE (AD) IS A FATAL NEURODEGENERATIVE DISEASE CHARACTERIZED BY PROGRESSIVE COGNITIVE DECLINE AND BRAIN PATHOLOGIES INCLUDING AMYLOID-B (AB) PEPTIDE DEPOSITION, HYPERPHOSPHORYLATED TAU ACCUMULATION, INFLAMMATION, AND SYNAPTIC AND NEURONAL LOSS. IN ADDITION TO PROTEIN PATHOLOGY, THE ABNORMAL ACCUMULATION OF LIPIDS IN AD BRAINS - ORIGINALLY DESCRIBED BY ALZHEIMER HIMSELF IN HIS 1907 PUBLICATION - HAS RECENTLY BEEN REDISCOVERED AS AN IMPORTANT FACTOR IN AD. MANY RECENT DISCOVERIES IN ALZHEIMER'S DISEASE RAISE QUESTIONS OF HOW LIPID-RICH MICRODOMAINS WITHIN CELL MEMBRANES KNOWN AS LIPID RAFTS MIGHT PLAY ROLES IN ALZHEIMER'S PATHOLOGY; WHY CONTACT POINTS BETWEEN MITOCHONDRIA AND THE ENDOPLASMIC RETICULUM (ER), KNOWN AS MITOCHONDRIA-ASSOCIATED ER MEMBRANES OR MAMS, INCREASE IN AD AND ARE IMPACTED BY THE PRESENCE OF APOE4, THE STRONGEST GENETIC RISK FACTOR FOR LATE-ONSET AD; HOW INTRANEURONAL AGGREGATION OF TAU AND TOXIC AB TRIGGER ER STRESS IN EARLY STAGES OF AD; WHY CHANGES IN MITOCHONDRIAL MORPHOLOGY SUCH AS FRAGMENTATION AND ELONGATION OCCUR IN AD; AS WELL AS COUNTLESS OTHER RECENT DISCOVERIES. ONE RECENT EXAMPLE FROM OUR TEAMS WAS A DEMONSTRATION OF ACCUMULATION OF NEUTRAL LIPID DROPLETS AND CHOLESTEROL IN GLIAL CELLS HARBORING THE APOE4 ALLELE IN THE GENE CODING FOR APOLIPOPROTEIN E (APOE), ONE OF THE MOST SIGNIFICANT GENETIC RISK FACTORS FOR DEVELOPING AD. THE PRESENCE OF APOE4 LED TO LD ACCUMULATION IN ASTROCYTES, MICROGLIA, AND OLIGODENDROCYTES. WHILE THESE FINDINGS CLEARLY SUGGEST THAT SUBCELLULAR ORGANELLE ORGANIZATION AND MORPHOLOGIES PLAY IMPORTANT ROLES IN THE DEVELOPMENT OF AD, THE MECHANISMS MEDIATING THESE ROLES REMAIN UNCLEAR, LARGELY DUE TO THE LACK OF ANALYTICAL TOOLS THAT ALLOW THE UNAMBIGUOUS CHARACTERIZATION OF INTRACELLULAR STRUCTURES IN BRAIN TISSUE FROM ANIMAL MODELS OF AD AND FROM HUMAN AD PATIENTS. THE STANDARD METHOD FOR INVESTIGATING MORPHOLOGICAL CHARACTERISTICS OF ORGANELLES IS ELECTRON MICROSCOPY (EM) WHICH STRUGGLES TO IDENTIFY SPECIFIC BIOMOLECULES AMIDST ORGANELLE ARCHITECTURE. OUR RECENT INVENTION OF EXPANSION MICROSCOPY (EXM) ALLOWS NANOSCALE IMAGING OF BIOLOGICAL SPECIMENS, INCLUDING MOLECULAR CONTRAST, WITH CONVENTIONAL MICROSCOPES, AND HAS BEEN EMPLOYED IN STUDIES ON THE GOLGI APPARATUS, THE ER, MITOCHONDRIA, AND MYELIN. HERE WE PROPOSE TO EXTEND THE EXM TOOLBOX TO CONFRONT, HEAD-ON, THE KEY NEEDS OF ALZHEIMER'S LIPID RESEARCH. SPECIFICALLY, WE WILL (AIM 1) OPTIMIZE, AND VALIDATE, A FORM OF EXM THAT COMBINES LIPID PRESERVATION AND STAINING, MULTIPLEXED ANTIBODY STAINING, AND EXPANSION MICROSCOPY - WHICH WE CALL MULTIPLEXED ULTRASTRUCTURE EXPANSION MICROSCOPY (MULTIPLEX-UMEXM); (AIM 2) OPTIMIZE, AND VALIDATE, MULTIPLEX-UMEXM FOR HUMAN BRAIN TISSUE; (AIM 3) PERFORM A COMPREHENSIVE CHARACTERIZATION OF LIPID ACCUMULATION AND ORGANELLES BY BRAIN CELL TYPE AND AD RISK GENOTYPE IN MOUSE AND HUMAN TISSUE. THE NET RESULT OF THIS GRANT WILL BE A TOOLBOX THAT ANYONE IN BIOLOGY CAN USE TO CHARACTERIZE LIPID AND ORGANELLE PROPERTIES, WITH NANOSCALE PRECISION AND MOLECULAR CONTRAST, IN DISEASES SUCH AS ALZHEIMER'S DISEASE, AS WELL AS THE VALIDATION DATA TO SHOW ITS UTILITY.